Evidence map›Paper›PMID 37455459›Full record

ReviewCurrent medicinal chemistry2024

Recent Developments in Coumarin Derivatives as Neuroprotective Agents.

Prakash Shyambabu Mishra, Amit Kumar, Kamalpreet Kaur, Vikas Jaitak

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current medicinal chemistry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
6.1field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 25 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Biochemistry and biophysics reports · 2026
    Article
  6. Article
  7. Coumarin-Dithiocarbamate Derivatives as Biological Agents.International journal of molecular sciences · 2025
    Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Coumarin: A natural solution for alleviating inflammatory disorders.Current research in pharmacology and drug discovery · 2024
    Review
  13. Article
  14. Article
  15. The Protective Action ofBioMed research international · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Prakash Shyambabu MishraDepartment of Pharmaceutical Sciences and Natural Products, Central University of Punjab, Ghudda, Bathinda (Pb.), 151401, India.
Amit KumarDepartment of Pharmaceutical Sciences and Natural Products, Central University of Punjab, Ghudda, Bathinda (Pb.), 151401, India.
Kamalpreet KaurDepartment of Pharmaceutical Sciences and Natural Products, Central University of Punjab, Ghudda, Bathinda (Pb.), 151401, India.
Vikas JaitakDepartment of Pharmaceutical Sciences and Natural Products, Central University of Punjab, Ghudda, Bathinda (Pb.), 151401, India.
Central University of Punjab · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundNeurodegenerative diseases are among the diseases that cause the foremost burden on the health system of the world. The diseases are multifaceted and difficult to treat because of their complex pathophysiology, which includes protein aggregation, neurotransmitter breakdown, metal dysregulation, oxidative stress, neuroinflammation, excitotoxicity, etc. None of the currently available therapies has been found to be significant in producing desired responses without any major side effects; besides, they only give symptomatic relief otherwise indicated off-episode relief. Targeting various pathways, namely choline esterase, monoamine oxidase B, cannabinoid system, metal chelation, β-secretase, oxidative stress, etc., may lead to neurodegeneration. By substituting various functional moieties over the coumarin nucleus, researchers are trying to produce safer and more effective neuroprotective agents.

objectivesThis study aimed to review the current literature to produce compounds with lower side effects using coumarin as a pharmacophore.

methodsIn this review, we have attempted to compile various synthetic strategies that have been used to produce coumarin and various substitutional strategies used to produce neuroprotective agents from the coumarin pharmacophore. Moreover, structure-activity relationships of substituting coumarin scaffold at various positions, which could be instrumental in designing new compounds, were also discussed.

resultsThe literature review suggested that coumarins and their derivatives can act as neuroprotective agents following various mechanisms.

conclusionVarious studies have demonstrated the neuroprotective activity of coumarin due to an oxaheterocyclic loop, which allows binding with a broad array of proteins, thus motivating researchers to explore its potential as a lead against various neurodegenerative diseases.

Indexed as

CoumarinsNeurodegenerative DiseasesNeuroprotective AgentsAnimalsHumansStructure-Activity RelationshipCoumarinsNeuroprotective AgentsChE inhibitorscoumarinsMAO-B inhibitorsneuro.neurodegenerationNeuroprotection

Identifiers

PMID37455459
OpenAlexW4384492982

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.